H.C. Wainwright resumed coverage on RAPT Therapeutics with a new price target
$RAPT
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $6.00 | Buy | H.C. Wainwright |
| 12/26/2024 | $10.00 | Neutral → Buy | H.C. Wainwright |
| 11/13/2024 | $7.00 → $2.00 | Buy → Hold | Stifel |
| 11/11/2024 | $8.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 11/11/2024 | Neutral → Underweight | JP Morgan | |
| 5/14/2024 | Outperform → Peer Perform | Wolfe Research | |
| 5/10/2024 | Buy → Neutral | Guggenheim | |
| 5/10/2024 | $13.00 → $4.00 | Overweight → Equal Weight | Barclays |
S-8 - RAPT Therapeutics, Inc. (0001673772) (Filer)
8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)
8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00
H.C. Wainwright upgraded RAPT Therapeutics from Neutral to Buy and set a new price target of $10.00
Stifel downgraded RAPT Therapeutics from Buy to Hold and set a new price target of $2.00 from $7.00 previously
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) (the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol "RAPT" with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a rever
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ETUBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025 To access the live webcast or subsequent archived recording of the Goldman Sa
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. "The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat patients with food allergy and are making good progress toward our planned initiation of a Phase 2b trial in the second half of 2025," said Brian Wong, President and CEO of RAPT. "We are